Trial Profile
A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children With Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Givinostat (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Italfarmaco
- 09 Oct 2020 According to an Italfarmaco media release, results from this study were published in Neuromuscular Disorder Journal (2016).
- 09 Oct 2020 Results presented in an Italfarmaco media release.
- 04 Dec 2017 Status changed from active, no longer recruiting to completed.